TERESA PÉREZ

Dr. TERESA PÉREZ


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MGMonica Barron Gonzalez
Monica Barron Gonzalez
MRMartha Cecilia Rosales-hernendez
Martha Cecilia Rosales-hernendez
AGANTONIO ABAD GARCIA
ANTONIO ABAD GARCIA
AOAna L. Ocampo-Néstor
Ana L. Ocampo-Néstor
JSJosé Martín Santiago-Quintana
José Martín Santiago-Quintana
Marvin A. Soriano-UrsuaMarvin A. Soriano-Ursua
Marvin A. Soriano-Ursua
Preclinical and clinical evidence supports melatonin and its analogues as potential treatment for diseases involving cognitive deficit such as Alzheimer’s disease. In this work, we evaluated by in silico studies a set of boron-containing melatonin analogues on MT1 and MT2 receptors. Then, we synthesized a compound (borolatonin) identified as potent agonist. After chemical characterization, its evaluation in a rat model with cognitive deficit showed that it induced ameliorative effects such as those induced by equimolar administration of melatonin in behavioral tests and in neuronal immunohistochemistry assays. Our results suggest the observed effects are by means of action on the melatonin system. Further studies are required to clarify the mechanism(s) of action, as the beneficial effects on disturbed memory by gonadectomy in male rats are attractive.

19 March 2025 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
Marvin A. Soriano-UrsuaMarvin A. Soriano-Ursua
Marvin A. Soriano-Ursua
MMMarlet Martinez
Marlet Martinez
AKAhmet Kilic
Ahmet Kilic
TPTERESA PÉREZ
TERESA PÉREZ
MHMiriam Hernández-Zamora
Miriam Hernández-Zamora
EFEunice D. Farfán-García
Eunice D. Farfán-García
Boron-containing compounds (BCCs) have been proposed for the treatment of diabetes and its complications. Recent studies have reported an improvement in the design and development of pharmaceutical formulations (often gels) containing boric acid applied to the foot ulcers of humans diagnosed with diabetes. The proposed mechanisms of action of boric acid include antimicrobial effects, the modulation of inflammation and metabolism, and the induction of cell differentiation. On the other hand, recent studies have suggested that boronic acids are potent antibacterial and antifungal compounds, effective modulators of inflammation, and inducers of vascular regeneration as well as inducers of healing, and they confer attractive properties such as adhesion, interaction, and the formation of complexes in formulations. Moreover, only a handful of studies conducted in animals have suggested the effective role of some BCCs as potent enhancers of wound healing, including their actions on induced and/or infected wounds in animals with disrupted metabolism. Also, it should be mentioned that no strong interactions between boric acid and the boronic acids present in formulations have been described. The developed combination could act as an additive and complementary therapy in the treatment of diabetic ulcers in humans. Further studies are required to support the hypothesis that this combination acts through diverse mechanisms to improve healing while avoiding or limiting a local or disseminated infection. Furthermore, the safety of BCCs used for foot ulcers should be established, as should the role of these formulations as a complementary therapy in current protocols for treating patients with diabetic foot ulcers.